8-1-2022: Actemra (tocilizumab) was called in again against a very tough opponent, Familial Mediterranean fever https://t.co/DwM8FYv3Jq https://t.co/9nhQmpRanh https://t.co/bSXwnhWLrq https://t.co/CptC15nNGR https://t.co/pJ4vfHYMzs https://t.co/oX5x0g2WhE
Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial - PubMed http
Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial. https://t.co
Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial. https://t.co